Prolor Biotech (PBTH +8.2%) hires Jefferies Group to evaluate strategic alternatives. An unnamed source says the company has drawn interest from big pharma over the past 12 months, but notes PBTH has not decided to sell itself. SA contributor Daniel Lauchheimer's article suggesting the stock has "unlimited upside" looks prescient. (See also: PBTH gets orphan drug designation)